Tri-Service General Hospital
Welcome,         Profile    Billing    Logout  
 38 Trials 
82 Trials

   

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Twelves, Chris
ELAINE 3, NCT05696626: Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation

Recruiting
3
500
Europe, Canada, US, RoW
Lasofoxifene in combination with abemaciclib, Fulvestrant in combination with abemaciclib
Sermonix Pharmaceuticals Inc.
Metastatic Breast Cancer
04/27
04/28
NCT04796324 / 2020-004610-35: Anti-tumor Effect of Ixabepilone in Metastatic Breast Cancer (mBC) Selected by the Ixabepilone DRP.

Recruiting
2
60
Europe
Ixabepilone Injection
Allarity Therapeutics, Allarity Therapeutics
Metastatic Breast Cancer
10/24
11/25
ALS-6000-101, NCT04969835: A Study Evaluating the Safety, Pharmacokinetics and Early Efficacy of AVA6000 in Solid Tumours

Recruiting
1
158
Europe, US
AVA6000
Avacta Life Sciences Ltd
Salivary Gland Tumor, Urothelial Carcinoma, Ovarian Carcinoma, Breast Cancer, Soft Tissue Sarcoma
03/26
08/26
Steg, Gabriel P
NCT06292013: A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)

Recruiting
3
12500
Europe, Canada, Japan, US, RoW
Lepodisiran Sodium, LY3819469, Placebo
Eli Lilly and Company
Atherosclerotic Cardiovascular Disease (ASCVD), Elevated Lp(a)
03/29
03/29
RITA-MI2, NCT05211401: Rituximab in Patients with ST-elevation Myocardial Infarction

Recruiting
2
558
Europe
Active arm 200 mg, Active arm 1000 mg, Placebo arm
Assistance Publique - Hôpitaux de Paris, Institut National de la Santé Et de la Recherche Médicale, France
ST Elevated Myocardial Infarction
10/26
04/27
AI-ATTR-ECHO, NCT06328075: Artificial Intelligence to Assist the Echocardiographic Identification of Transthyretin Cardiac Amyloidosis

Recruiting
N/A
15000
Europe
non interventional study
Algalarrondo Vincent, Bichat Hospital, Bioquantis
Amyloid Cardiomyopathy, Transthyretin Amyloid Cardiomyopathy, Transthyretin Cardiac Amyloidosis
01/25
01/26
Tsai, Chon-Haw
NCT03413384: To Assess the Efficacy and Safety of Ceftriaxone in Patients With Mild to Moderate Parkinson's Disease Dementia

Recruiting
2
106
RoW
Ceftriaxone, Ceftriaxone Sandoz powder for IV Injection, Placebo
BrainX Corporation, Virginia Contract Research Organization Co., Ltd.
Parkinson's Disease Dementia
12/24
03/25
NCT04434768: Evaluate the Safety and Explore Efficacy of Umbilical Cord Mesenchymal Stem Cells in Acute Ischemic Stroke

Recruiting
1
14
RoW
UMSC01
Ever Supreme Bio Technology Co., Ltd.
Acute Stroke
12/25
12/25
NCT05092243: Exploit the Functional Higher Neural Connectivity and Electrophysiological Intervention of Freezing of Gait in PD and PSP During Different Ambulatory Complexities

Recruiting
N/A
40
RoW
Transcranial direct current stimulation
China Medical University Hospital, Ministry of Science and Technology, Taiwan
Transcranial Direct Current Stimulation
07/22
07/24
NCT06505460: Exploring the Possible Beneficial Impact of Non-invasive and Invasive Neuromodulation on Freezing of Gait in Parkinson's Disease During Different Ambulatory Complexities: An Electrophysiological and fMRI Study

Recruiting
N/A
20
RoW
Transcranial direct current stimulation
China Medical University Hospital, Ministry of Science and Technology, Taiwan
Transcranial Direct Current Stimulation
07/25
07/27
Chen, Yeu-Chin
BRUIN-MCL-321, NCT04662255 / 2020-004553-72: Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL)

Active, not recruiting
3
500
Europe, Canada, Japan, US, RoW
Pirtobrutinib, LOXO-305, LY3527727, Ibrutinib, Imbruvica, Acalabrutinib, Calquence, Zanubrutinib, Brukinsa
Loxo Oncology, Inc., Eli Lilly and Company
Lymphoma, Mantle-Cell
12/25
07/26
NCT05981274: A Study on the Bone-health Effectiveness of Applying Recombinant Factor VIII Fc (rFVIIIFc) to Patients With Hemophilia A (Prototype A)

Recruiting
N/A
45
RoW
serum biomarker.
Tri-Service General Hospital
Severe Hemophilia A Without Inhibitor
12/27
12/27
NCT04158934: A Long-term Study of ADYNOVI/ADYNOVATE in Participants With Haemophilia A

Active, not recruiting
N/A
207
Europe, US, RoW
ADYNOVI/ADYNOVATE, Antihaemophilic Factor [Recombinant] PEGylated rurioctocog alfa pegol, TAK-660, BAX 855
Baxalta now part of Shire
Hemophilia A
02/30
02/30
Li, Gang
HEARTRIP, NCT03809273: Effects of Yangxinshi Pills on the Exercise Tolerance Compared With Trimetazidine in Patients After PCI

Recruiting
4
668
RoW
Yangxinshi, Trimetazidine, Yangxinshi mimic, Trimetazidine mimic
Shenyang Northern Hospital
Percutaneous Coronary Intervention
12/20
12/20
ENRICH-AF, NCT03950076 / 2019-002075-33: EdoxabaN for IntraCranial Hemorrhage Survivors with Atrial Fibrillation

Active, not recruiting
4
948
Europe, Canada, US, RoW
Edoxaban, Lixiana, Savaysa, Non-anticoagulant medical therapy
Population Health Research Institute
Intracranial Hemorrhages, Atrial Fibrillation
04/26
10/26
NCT05182463: Peginterferon Treatment Study for Inactive Chronic Hepatitis B Patients

Recruiting
4
5000
RoW
Peginterferon Alfa-2B, Nucleoside Analogs
Third Affiliated Hospital, Sun Yat-Sen University
Hepatitis B, Chronic
12/26
11/29
INTERACT4, NCT03790800: Intensive Ambulance-delivered Blood Pressure Reduction in Hyper-Acute Stroke Trial

Completed
3
2425
RoW
urapidil, Intensive BP lowing
The George Institute for Global Health, China, Shanghai East Hospital, China, First Affiliated Hospital of Chengdu Medical College, China, Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital, China
Stroke, Acute, Cerebrovascular Disorders
11/23
11/23
EAST, NCT06773364: Early Initiated Ambulance-delivered Levetiracetam and Headposition in Hyper-acute Stroke Trial

Not yet recruiting
3
2423
NA
Levetiracetam, Guide-recommended management, The lying flat (0°) head position, The sitting-up (≥30°) head position
Shanghai East Hospital
Suspected Stroke
12/28
12/29
ATEM, NCT05416476: Anisodine Hydrobromide For The Preventive Treatment Of Episodic Migraine

Recruiting
3
288
RoW
Anisodine Hydrobromide, Anisodine Hydrobromide placebo
Second Affiliated Hospital, School of Medicine, Zhejiang University
Migraine Without Aura, Migraine With Aura
10/25
12/25
TRAILBLAZER-ALZ 5, NCT05508789: A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disease

Recruiting
3
1500
Europe, RoW
Donanemab, (LY3002813), Placebo
Eli Lilly and Company
Alzheimer Disease, Dementia, Brain Diseases, Central Nervous System Diseases, Nervous System Diseases, Tauopathies, Neurodegenerative Diseases, Neurocognitive Disorders, Mental Disorders
04/27
04/27
OPTIMISTIC, NCT04851457: One Pass Tirofiban In Management of Ischemic Stroke Thrombectomy In China

Completed
2
200
RoW
Intravenous tirofiban combination therapy, Tirofiban
Shanghai East Hospital, Shanghai 6th People's Hospital, Ningbo No. 1 Hospital, Zhangzhou Municipal Hospital of Fujian Province, Shanghai 7th People's Hospital, Jinan Central Hospital, Xuchang Central Hospital
Ischemic Stroke
07/23
10/23
PANDORA, NCT04995016: Pembrolizumab and Axitinib as Neoadjuvant Therapy for Locally Advanced Non-metastatic Clear Cell Renal Cell Carcinoma

Not yet recruiting
2
18
RoW
Pembrolizumab, Keytruda, Axitinib, Inlyta
Tianjin Medical University Second Hospital
Renal Cell Carcinoma, Clear Cell Renal Cell Carcinoma
08/22
08/23
PM8002-A001, NCT05918445: PM8002 in the Treatment of Patients With Advanced Solid Tumors

Recruiting
1/2
380
RoW
PM8002
Biotheus Inc.
Malignant Neoplasm
11/25
11/25
NCT04093336: Effect of Mesenchymal Stem Cells(MSCs) Transplantation for Acute Cerebral Infarction Patients

Recruiting
1/2
120
RoW
human umbilical cord mesenchymal stem cells, Placebo, standardized treatment
Shanghai East Hospital
Infarction, Middle Cerebral Artery, Infarction, Anterior Cerebral Artery, Cerebral Infarction, Stroke, Ischemic, Acute Stroke, Brain Infarction, Infarction, PCA, Infarction, Posterior Circulation, Brain
12/24
12/24
NCT04137926: A Multicenter Study on the Diagnosis and Intervention of New Biomarkers on the Prodromal Stage of Alzheimer's Disease

Recruiting
N/A
360
RoW
MicRNAs battery
Shanghai Mental Health Center
Alzheimer's Disease
08/22
11/22
NCT06468436: Dexmedetomidine-Esketamine Combination for Sedation and Analgesia in ICU Patients

Not yet recruiting
N/A
1508
RoW
Dexmedetomidine-Esketamine Combination, Dexmedetomidine hydrochloride, Esketamine hydrochloride, Dexmedetomidine
Peking University First Hospital, Peking University International Hospital, Tianjin Medical University General Hospital
Aged, Intensive Care Units, Ventilators, Mechanical, Dexmedetomidine, Esketamine, Delirium
06/30
12/30
NCT05755776: The Efficacy and Safety of Tenofovir Amibufenamide to Treat Low-level Viraemia After Entecavir Treatment

Recruiting
N/A
204
RoW
TMF, Heng Mu
The Second Affiliated Hospital of Chongqing Medical University, Jiangsu Hansoh Pharmaceutical Co., Ltd.
Chronic Hepatitis B
12/24
12/24
NCT04995159: Optimized Antiplatelet Therapy in Patients With CHD After Implantation of NeoVasâ„¢ BRS System

Not yet recruiting
N/A
2150
RoW
Single anti-platelet therapy, SAPT strategy, Dual anti-platelet therapy, DAPT strategy
Lepu Medical Technology (Beijing) Co., Ltd.
Coronary Heart Disease
01/26
01/28
Ho, Ching-Liang
NCT04169178: Evaluate Safety, Tolerability and PK of HLX55 in Patients With Advanced Solid Tumors With Different cMET Status

Recruiting
1
98
RoW
HLX55, HLX55 monoclonal antibody for Injection
Henlix, Inc
Solid Tumor, Adult
12/22
12/22
TEACH, NCT04281420: A Study of Evaluating Dual Inhibitor of PAK4 and NAMPT ATG-019 in Advanced Solid Tumors or Non-Hodgkin's Lymphoma

Terminated
1
20
RoW
ATG-019, KPT-9274, ATG-019 + Niacin ER
Antengene Therapeutics Limited
Solid Tumor, Non-Hodgkin's Lymphoma
10/23
10/23
NCT02347228: Evaluate Safety, Tolerability, PK, Preliminary Clinical Activity of OB318 in Patients With Advanced Solid Malignancies

Recruiting
1
30
RoW
OB318 capsule
Oneness Biotech Co., Ltd.
Advanced Solid Malignancies
12/24
12/24
Khan, Sarah
FINER, NCT04650581: Fulvestrant and Ipatasertib for Advanced HER-2 Negative and Estrogen Receptor Positive (ER+) Breast Cancer Following Progression on First Line CDK 4/6 Inhibitor and Aromatase Inhibitor

Active, not recruiting
3
250
Canada, RoW
Ipatasertib, Fulvestrant, Placebo
Canadian Cancer Trials Group, Hoffmann-La Roche
Breast Cancer
12/24
12/26
ELAINE 3, NCT05696626: Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation

Recruiting
3
500
Europe, Canada, US, RoW
Lasofoxifene in combination with abemaciclib, Fulvestrant in combination with abemaciclib
Sermonix Pharmaceuticals Inc.
Metastatic Breast Cancer
04/27
04/28
LIBRETTO-432, NCT04819100 / 2020-005191-35: A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC)

Recruiting
3
170
Europe, Canada, Japan, US, RoW
Selpercatinib, LY3527723, LOXO-292, Placebo
Loxo Oncology, Inc., Eli Lilly and Company
Carcinoma, Non-Small-Cell Lung
05/27
08/32
LUCINDA, NCT03649724: The Trial: LeUprolide Plus Cholinesterase Inhibition to Reduce Neurological Decline in Alzheimer's

Recruiting
2
180
US
Placebo, Eligard 22.5Mg Suspension for Injection
Weill Medical College of Cornell University, National Institute on Aging (NIA), Tolmar Pharmaceuticals
Alzheimer Disease, Mild Cognitive Impairment
12/25
02/26
FAIM, NCT04920708: Fulvestrant, Ipatasertib and CDK4/6 Inhibition in Metastatic ER+/HER2- Breast Cancer Patients Without ctDNA Suppression

Recruiting
2
324
Europe
Ipatasertib 300mg, RG7440, Fulvestrant 500g, Faslodex, Palbociclib 75mg-125mg, Ibrance, CDK4/6 Inhibitor, Abemaciclib / Ribociclib / Palbociclib
Royal Marsden NHS Foundation Trust, Pfizer, Hoffmann-La Roche
Metastatic Breast Cancer, ER+ Breast Cancer, Advanced Breast Cancer
09/26
09/26
TRAK-ER, NCT04985266 / 2020-004022-36: A Trial of Early Detection of Molecular Relapse With Circulating Tumour DNA Tracking and Treatment With Palbociclib Plus Fulvestrant Versus Standard Endocrine Therapy in Patients With ER Positive HER2 Negative Breast Cancer

Recruiting
2
1100
Europe
Palbociclib 125Mg Tab, Fulvestrant injection, Tamoxifen, Letrozole, Exemestane, Anastrozole
Royal Marsden NHS Foundation Trust, Pfizer, AstraZeneca, Institute of Cancer Research, United Kingdom, UNICANCER, Gustave Roussy, Cancer Campus, Grand Paris, Invitae Corporation
ER+ Breast Cancer, HER2-negative Breast Cancer
09/27
09/30
PAveMenT, NCT04360941: Palbociclib and Avelumab in Metastatic AR+ Triple Negative Breast Cancer

Recruiting
1
45
Europe
Palbociclib, Ibrance, Avelumab, Bavencio
Royal Marsden NHS Foundation Trust, Pfizer, Breast Cancer Now
Triple Negative Breast Cancer, Locally Advanced Breast Cancer, Recurrent Breast Cancer, Metastatic Breast Cancer, ER+ Breast Cancer, HER2-positive Breast Cancer
07/25
12/25
Dai, Ming-Shen
ELAINE 3, NCT05696626: Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation

Recruiting
3
500
Europe, Canada, US, RoW
Lasofoxifene in combination with abemaciclib, Fulvestrant in combination with abemaciclib
Sermonix Pharmaceuticals Inc.
Metastatic Breast Cancer
04/27
04/28
NCT04616209: Allogeneic PB103 (NK Cells) Therapy in Non-small Cell Lung Cancer (NSCLC) Patients

Recruiting
1/2
24
RoW
donor-derived NK cell infusion
Precision Biotech Taiwan Corp., Tri-Service General Hospital
Non-small Cell Lung Cancer
12/24
12/24
iinnovate-1, NCT03215030 / 2021-006038-37: A Study of Modakafusp Alfa on Adult Participants With Relapsed/Refractory Multiple Myeloma

Completed
1/2
272
Europe, Canada, Japan, US, RoW
Modakafusp alfa, TAK-573, TEV-48573, Dexamethasone
Takeda, Takeda Development Center Americas, Inc.
Multiple Myeloma
07/24
11/24
NCT05036486: The Registry of Genetic Alterations of Taiwan Biliary Tract Cancer

Recruiting
N/A
400
RoW
next-generation sequencing
National Health Research Institutes, Taiwan, National Taiwan University Hospital, Taipei Veterans General Hospital, Taiwan, Tri-Service General Hospital, Chang Gung Medical Foundation (Linkou Branch), Taipei Medical University Shuang Ho Hospital, Koo Foundation Sun Yat-Sen Cancer Center, China Medical University Hospital, National Cheng-Kung University Hospital, Kaohsiung Medical University Chung-Ho Memorial Hospital, Chang Gung Memorial Hospital, Chang Gung Memorial Hospital, Chiayi, Taoyuan General Hospital, Ministry of Health and Welfare, Mackay Memorial Hospital
Biliary Tract Cancer (BTC)
12/30
12/30
Chen, Hsiang-Cheng
NCT04314531: Efficacy and Safety of Tildrakizumab Compared to Placebo in Anti-TNF naïve Subjects With Active Psoriatic Arthritis II (INSPIRE 2)

Active, not recruiting
3
292
Europe, Japan, US, RoW
TILD, matching placebo injections
Sun Pharmaceutical Industries Limited
Active Psoriatic Arthritis
09/24
12/24
NCT04314544: Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1)

Recruiting
3
472
Europe, Canada, US, RoW
TILD, matching placebo injections
Sun Pharmaceutical Industries Limited
Active Psoriatic Arthritis
05/25
02/26
NCT05123586: A IMMA Master Protocol: A Study of LY3361237 in Participants With at Least Moderately Active Systemic Lupus Erythematosus

Terminated
2
85
Europe, US, RoW
LY3361237, Placebo
Eli Lilly and Company
Systemic Lupus Erythematosus
12/23
12/23
NCT05807529: A Study to Evaluate the Safety and Efficacy of 2ccPA in Patients With Symptomatic Knee Osteoarthritis

Active, not recruiting
1/2
136
RoW
2ccPA, 2-carba-cyclic phosphatidic acid, Placebo
Orient Europharma Co., Ltd.
Osteoarthritis, Knee
12/24
12/24
Yeh, Chin-Bin
NCT05974241: Irritability in Children With ADHD and Emotion Dysregulation

Completed
4
36
RoW
Methylphenidate, aripiprazole, and combination, Ritalin/Concerta, Abilify, and combination
Tri-Service General Hospital
Irritable Mood, ADHD
04/22
04/22
NCT05043805: Dextromethorphan Added on for Children With Chronic Irritability

Enrolling by invitation
4
120
RoW
Dextromethorphan, regrow, placebo
Tri-Service General Hospital
Irritable Mood
04/24
06/24
Chen, Yeu Chin
OLYMPIA-2, NCT06097364: A Trial to Learn if Odronextamab Combined With Chemotherapy is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Chemotherapy for Adult Participants With Follicular Lymphoma

Recruiting
3
733
Europe, US, RoW
Odronextamab, REGN1979, Rituximab, Rituxan, Cyclophosphamide, Cytoxan, Doxorubicin, Adriamycin, Vincristine, Oncovin, Prednisone/Prenisolone, Deltasone/Omnipred
Regeneron Pharmaceuticals
Follicular Lymphoma (FL)
07/29
07/29
Huang, Tzu-Chuan
NCT03763604: Named Patient Use Program to Provide Abemaciclib (LY2835219) for the Treatment of Metastatic Breast Cancer

Approved for marketing
N/A
Europe, Canada, RoW
Abemaciclib, LY2835219
Eli Lilly and Company
Metastatic Breast Cancer
 
 
Dai, Min
NCT06180889: Factor XI inhibiTion for the Prevention of Venous Thromboembolism in Patients Undergoing Total Knee Arthroplasty

Recruiting
2
240
RoW
Enoxaparin, KN060 Low, KN060 Middle, KN060 Hight
Suzhou Alphamab Co., Ltd.
Knee Arthroplasty, Total
12/25
04/26
NCT04616209: Allogeneic PB103 (NK Cells) Therapy in Non-small Cell Lung Cancer (NSCLC) Patients

Recruiting
1/2
24
RoW
donor-derived NK cell infusion
Precision Biotech Taiwan Corp., Tri-Service General Hospital
Non-small Cell Lung Cancer
12/24
12/24
Ma, Hsin-I
NCT03008148: Phase II/III Trial of CCRT With or Without JP001 for Newly Diagnosed GBM

Recruiting
2/3
288
RoW
CCRT, Temozolomide, Chemotherapy, Siroquine, JP001
Johnpro Biotech, Inc.
Glioblastoma
04/25
04/25
Lin, Wei-Hsiang
NCT06292013: A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)

Recruiting
3
12500
Europe, Canada, Japan, US, RoW
Lepodisiran Sodium, LY3819469, Placebo
Eli Lilly and Company
Atherosclerotic Cardiovascular Disease (ASCVD), Elevated Lp(a)
03/29
03/29
Lu, Chueng-He
NCT05115955: PO Pain Management with Extended-release Dinalbuphine Sebacate in Patients Undergoing Arthroscopic Shoulder Surgery

Completed
4
76
RoW
DS group, NALDEBAIN®, Control group, Sesame oil
Tri-Service General Hospital
Anesthesiology, Orthopedic
05/24
06/24
Hsu, Shiuh-Liang
NCT06381986: Efficacy and Safety of SHJ002 Ophthalmic Solution in the Treatment of Corneal Erosion in Sjogren's Patients

Active, not recruiting
2
122
RoW
SHJ002, Vehicle
Sunhawk Vision Biotech, Inc.
Corneal Erosion
01/25
02/25
Pan, Ru-Yu
NCT05115955: PO Pain Management with Extended-release Dinalbuphine Sebacate in Patients Undergoing Arthroscopic Shoulder Surgery

Completed
4
76
RoW
DS group, NALDEBAIN®, Control group, Sesame oil
Tri-Service General Hospital
Anesthesiology, Orthopedic
05/24
06/24
Pietrucha, Slavomir
NCT05711940: Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD

Recruiting
3
568
Europe, Canada, US, RoW
Psilocybin, COMP360
COMPASS Pathways
Treatment Resistant Depression
03/25
05/25
TRAILBLAZER-ALZ 5, NCT05508789: A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disease

Recruiting
3
1500
Europe, RoW
Donanemab, (LY3002813), Placebo
Eli Lilly and Company
Alzheimer Disease, Dementia, Brain Diseases, Central Nervous System Diseases, Nervous System Diseases, Tauopathies, Neurodegenerative Diseases, Neurocognitive Disorders, Mental Disorders
04/27
04/27
Bennys, Karim
DARIDOR-ALZ, NCT05924425: Daridorexant to Treat Insomnia in Patients With Mild Cognitive Impairment and Mild to Moderate Alzheimer Disease

Recruiting
4
62
Europe
Daridorexant 50 mg, Placebo, Polysomnography, Neuropsychological assessment, Questionnaires on sleep and behavioural problems, Actimetrics, 24-hour Ambulatory Blood Pressure Monitoring (ABPM, Biomarker assay
University Hospital, Montpellier, Idorsia Pharmaceuticals Ltd.
Alzheimer Disease, Insomnia Disorder, Sleep
05/26
03/27
ENVISION, NCT05310071 / 2022-001671-14: A Study to Verify the Clinical Benefit of Aducanumab in Participants With Early Alzheimer's Disease

Terminated
3
1027
Europe, Canada, Japan, US, RoW
Aducanumab, BIIB037, Aducanumab-avwa, Aduhelm, Placebo
Biogen, Biogen Idec Research Limited
Alzheimer's Disease
08/24
08/24
TRAILBLAZER-ALZ 5, NCT05508789: A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disease

Recruiting
3
1500
Europe, RoW
Donanemab, (LY3002813), Placebo
Eli Lilly and Company
Alzheimer Disease, Dementia, Brain Diseases, Central Nervous System Diseases, Nervous System Diseases, Tauopathies, Neurodegenerative Diseases, Neurocognitive Disorders, Mental Disorders
04/27
04/27
NanoLi®_AD, NCT05423522 / 2021-001273-23: Clinical Safety and Efficacy Evaluation of NanoLithium® NP03 in Patients With Mild-to-severe Alzheimer's Disease

Completed
2
72
Europe
NanoLithium® NP03, Placebo
Medesis Pharma SA, MEDESIS Pharma SA
Alzheimer's Disease
01/24
10/24
CELIA, NCT05399888: A Study to Learn About the Safety of BIIB080 Injections and Whether They Can Improve Symptoms of Participants With Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild AD Dementia Between 50 to 80 Years of Age

Active, not recruiting
2
416
Europe, Canada, Japan, US, RoW
BIIB080, ISIS 814907, BIIB080-matching placebo
Biogen
Mild Cognitive Impairment Due to Alzheimer's Disease, Alzheimer's Disease Dementia
05/26
01/29
ALZAN, NCT05427448: Validation of Blood Biomarkers for Alzheimer's Disease

Recruiting
N/A
342
Europe
Measurement of amyloid and pTau blood biomarkers
University Hospital, Montpellier
Alzheimer Disease, Mild Cognitive Impairment, Dementia, Tauopathies
11/24
12/24
MICMALZ, NCT04841135: Blood Microbiota Signature of Alzheimer's Disease

Recruiting
N/A
120
Europe
Multiomics quantification, Polysomnography
University Hospital, Montpellier
Alzheimer Disease, Elderly With Normal Cognition
04/24
01/26
COGNIKET-MCI, NCT06347315: Evaluation of the Effects of a Nutritional Intervention of Ketogenic Medium-chain Triglycerides and B-vitamins on Cognitive Functioning in Older Adults With Mild Cognitive Impairment

Recruiting
N/A
380
Europe
BrainXpert, Placebo
Société des Produits Nestlé (SPN)
Mild Cognitive Impairment
12/27
12/27
MUSENGAGE, NCT06688968: Neuropsychological Profiles and Musical Engagement in Parkinson's and Alzheimer's Disease

Not yet recruiting
N/A
120
Europe
neuropsychologist interview, questionnaire
University Hospital, Montpellier, Laboratoire EPSYLON
Alzheimer Disease, Early Onset, Parkinsons Disease With Dementia, Non Pharmacological Intervention
12/25
12/25
ALFA3pilot, NCT05516667: Cohort of Patients with Alzheimer's Disease and Their Families.

Recruiting
N/A
1000
Europe
University Hospital, Toulouse, France Alzheimer
Alzheimer Disease
06/26
01/27
ALZ-OREX, NCT05629871: Biomarkers of Sleep-wake Cycle in Prodromal Alzheimer's Disease: Role in Cognitive Decline?

Recruiting
N/A
132
Europe
Polysomnography, Neuropsychological assessment, Questionnaires on sleep and behavioural problems, Actimetry, Fractional diuresis, Internal temperature measurement, Biomarker assay
University Hospital, Montpellier, Institut National de la Santé Et de la Recherche Médicale, France
Neuropathology
07/27
07/27
WAVE-APOE4, NCT05649514: Sleep Impairment in Subjects at Risk of Developing Alzheimer's Disease

Not yet recruiting
N/A
50
NA
Polysomnography, Neuropsychological assessment, Questionnaires on sleep and behavioural problems, Actimetrics, Biomarker assay
University Hospital, Montpellier, Institut National de la Santé Et de la Recherche Médicale, France
Neuropathology, Cognitive Decline, Sleep Disorder
08/27
12/27
yang, fu-chi
TRAILBLAZER-ALZ 5, NCT05508789: A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disease

Recruiting
3
1500
Europe, RoW
Donanemab, (LY3002813), Placebo
Eli Lilly and Company
Alzheimer Disease, Dementia, Brain Diseases, Central Nervous System Diseases, Nervous System Diseases, Tauopathies, Neurodegenerative Diseases, Neurocognitive Disorders, Mental Disorders
04/27
04/27
Wu, Yi-Ying
BRUIN CLL-321, NCT04666038: Study of LOXO-305 Versus Investigator's Choice (IdelaR or BR) in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Active, not recruiting
3
250
Europe, Canada, Japan, US, RoW
LOXO-305, Pirtobrutinib, Idelalisib, Zydelig, Bendamustine, Treanda, Treakisym, Ribomustin, Levact, Rituximab, Rituxan, MabThera, Truxima
Loxo Oncology, Inc., Eli Lilly and Company
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
08/23
05/27
Lu, Chieh Hua
SURMOUNT-MMO, NCT05556512: A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity

Active, not recruiting
3
15374
Europe, Canada, Japan, US, RoW
Tirzepatide, LY3298176, Placebo
Eli Lilly and Company
Obesity, Overweight
10/27
10/27
Shih, TungYuan Mr
NCT05557448: To Evaluate the Efficacy and Safety of TYNADOTE® in the Treatment of Acetaminophen Overdose

Recruiting
2
24
RoW
TYNADOTE, Placebo Oral Tablet
Sinew Pharma Inc., Taipei Veterans General Hospital, Taiwan
Hepatitis
12/26
12/26
NCT03451487: A Randomized, Single-blind, Parallel Group and Multiple - Dose Design Study

Completed
N/A
28
RoW
Panadol®, Acetaminophen, SafeTynadol®, SNP-810
Sinew Pharma Inc.
Acetaminophen Toxicity
12/22
12/22
NCT05563961: A Partial Randomized, Single-blind or Open-label, Dose-escalation With Multiple-dose Design Study to Evaluate the Pharmacokinetics of Acetaminophen and Its Toxic Metabolites With Panadol® and SafeTynadol® in Healthy Volunteers

Recruiting
N/A
48
RoW
Panadol®, SafeTynadol®
Sinew Pharma Inc.
Hepatitis, Pharmacology
06/24
12/24
Hsiong, ChengHuei Mr
NCT05557448: To Evaluate the Efficacy and Safety of TYNADOTE® in the Treatment of Acetaminophen Overdose

Recruiting
2
24
RoW
TYNADOTE, Placebo Oral Tablet
Sinew Pharma Inc., Taipei Veterans General Hospital, Taiwan
Hepatitis
12/26
12/26
NCT05563961: A Partial Randomized, Single-blind or Open-label, Dose-escalation With Multiple-dose Design Study to Evaluate the Pharmacokinetics of Acetaminophen and Its Toxic Metabolites With Panadol® and SafeTynadol® in Healthy Volunteers

Recruiting
N/A
48
RoW
Panadol®, SafeTynadol®
Sinew Pharma Inc.
Hepatitis, Pharmacology
06/24
12/24
Matus, Maria Guadalupe
NCT05911841: A Study of LY3454738 in the Treatment of Adult Participants With Moderate-to-Severe Atopic Dermatitis

Active, not recruiting
2
236
Europe, Canada, Japan, US, RoW
LY3454738, Placebo
Eli Lilly and Company
Atopic Dermatitis
06/25
03/26
Liao, Zhengluan
TRAILBLAZER-ALZ 5, NCT05508789: A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disease

Recruiting
3
1500
Europe, RoW
Donanemab, (LY3002813), Placebo
Eli Lilly and Company
Alzheimer Disease, Dementia, Brain Diseases, Central Nervous System Diseases, Nervous System Diseases, Tauopathies, Neurodegenerative Diseases, Neurocognitive Disorders, Mental Disorders
04/27
04/27
Chen, Yi-Hsien
NCT05911841: A Study of LY3454738 in the Treatment of Adult Participants With Moderate-to-Severe Atopic Dermatitis

Active, not recruiting
2
236
Europe, Canada, Japan, US, RoW
LY3454738, Placebo
Eli Lilly and Company
Atopic Dermatitis
06/25
03/26

Download Options